DVA vs EXEL: fair value comparison
DaVita Inc. and Exelixis, Inc. · Updated 2026-09-06
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, DVA currently sits closer to the top of our discount ranking. EXEL carries the stronger quality grade.
| DVA | EXEL | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $183.99 | $55.06 |
| 12-month range | $111.19–$240.09 | $38.06–$55.06 |
| Sector rank | #41 of 113 Healthcare | #46 of 113 Healthcare |
| Quality grade | C | A |
| Leverage | Low | Low |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | Undervalued | Fairly Valued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: DVA fair value analysis · EXEL fair value analysis